CMDR Application Process: Registration Steps for Class B/C/D Devices and Deficiency Responses

1. Key takeaways

The CMDR (Certificate of Medical Device Registration) is the registration certificate issued for Class B, Class C and Class D devices. The sequence runs: confirm the LTO and the classification, prepare a complete ASEAN CSDT technical file, notarise and Apostille the supporting documents, submit to the designated mailbox, pay the fee, go through CDRRHR technical review, answer any deficiency, and receive the certificate. The statutory review period is 180 days from acceptance. In practice the cycle is usually 6 to 9 months, and where a deficiency notice is issued it can stretch to 9 to 12 months.

• Everything above Class A follows the CMDR route; the CMDN notification route is not available to Class B, C or D products.
• The technical file has to be built to the ASEAN Common Submission Dossier Template, which is the shared format agreed by the ten ASEAN member states.
• 180 days is a ceiling on the regulator, not a planning assumption. Plan on 6 to 9 months and reserve 9 to 12 months where a deficiency is likely.
• Notarisation and Apostille sit on the critical path because they depend on external parties whose schedules the applicant does not control.
• The certificate is valid for 5 years and renewal must be filed within 90 days before expiry.

2. Legal basis

The registration obligation comes from Department of Health Administrative Order No. 2018-0002 of 26 January 2018, Section IV, item 5, which defines the CMDR and assigns it to Class B, Class C and Class D devices. The technical file format is the ASEAN Common Submission Dossier Template developed by ACCSQ-MDPWG and adopted as the common requirement across the ten ASEAN member states. Under FDA Advisory No. 2025-0189 submissions are directed to cdrrhr-productregistration@fda.gov.ph. Where the product has already been approved by an ASEAN national regulatory authority, FC No. 2022-008 of 27 September 2022 sets a target of 30 working days. Validity is 5 years with renewal within 90 days before expiry, and processing timelines are also governed by RA No. 11032, the Ease of Doing Business Act of 2018.

3. Expert insights

The CSDT is the skeleton of the process and the main determinant of the timeline. The template covers administrative documents, device description, conformity with the essential principles, design verification and validation, risk management, clinical evidence and labelling, among other modules. In GRZAN’s experience, the completeness of the CSDT at first submission correlates with the review cycle more strongly than any other single factor. A CSDT with gaps triggers a deficiency, and a deficiency is what turns a six-month file into a twelve-month file.

The 180 days is a legal maximum, not a target. Some Chinese-language material presents 180 days as the expected cycle, which misreads the provision. The statutory period is an upper bound that the regulator is expected to observe; the actual time depends on review workload, the number of deficiency rounds and how quickly the applicant responds. Plan on 6 to 9 months, and reserve 9 to 12 months where a deficiency is issued.

The response to a deficiency letter is a one-time opportunity. CDRRHR issues the notice during technical review, and the industry working figure for the response window is 30 days. That window is not a buffer that can be consumed repeatedly. An incomplete response leads to a Letter of Disapproval, at which point the file has to be started again. GRZAN manages a deficiency response as a formal project: the question list is broken down on the day the letter arrives, owners are assigned, and nothing is submitted until an internal pre-review has been completed.

Consistency review belongs before submission, not after the FDA finds the problem. The six deficiencies we see most often are an ISO 13485 certificate whose scope does not cover the submitted product, a risk management report that is missing or does not match the device, clinical evidence that is insufficient for the intended use, labelling that contains Chinese characters or lacks mandatory elements, an LOA without completed authentication, and model or product names that differ between documents. All six can be closed in an internal QC pass before the file leaves the company.

4. Practical recommendations

• Build the file module by module against the CSDT and close each module as it is finished. Review each module internally when it is completed instead of assembling the whole dossier at the end, when there is no time left to fix structural gaps.
• Use a deficiency rehearsal as pre-submission QC. Ask colleagues who did not draft the file to read it from the CDRRHR perspective, looking specifically for the four recurring problem areas: ISO 13485 scope, risk management, label language, and cross-document consistency.
• Set an internal SLA for deficiency responses. Break the question list down within 48 hours of receiving the letter and complete the internal pre-review 72 hours before the submission deadline.
• Where an ASEAN member state approval already exists, evaluate the Abridged pathway first. The eligibility conditions and the documentation consequences are set out in article 13 of this series.
• Start notarisation and Apostille in parallel with dossier drafting. These steps depend on external schedules, and treating them as a final step is the most common cause of a slipped submission date.

5. Verification checklist

• □ Product class and pathway confirmed: everything other than Class A requires a CMDR.
• □ Product is not an IVD and not a refurbished device (AO No. 2018-0002, Section III).
• □ CSDT modules are complete, checked against a module-by-module list.
• □ ISO 13485 certificate scope covers the submitted product.
• □ Risk management report matches the ISO 14971 version and reflects the actual device.
• □ Clinical evidence is proportionate to the risk class.
• □ LOA is notarised and Apostilled, with the original and an online verification record.
• □ Label is in English and carries all mandatory elements; proof approved.
• □ Submission channel and fee payment confirmed: designated mailbox plus Order of Payment.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com